Record Information |
---|
Version | 5.0 |
---|
Status | Expected but not Quantified |
---|
Creation Date | 2006-02-16 08:59:19 UTC |
---|
Update Date | 2022-03-07 02:49:10 UTC |
---|
HMDB ID | HMDB0001848 |
---|
Secondary Accession Numbers | |
---|
Metabolite Identification |
---|
Common Name | Imipramine |
---|
Description | Imipramine, also known as tofranil or imizine, belongs to the class of organic compounds known as dibenzazepines. Dibenzazepines are compounds with two benzene rings connected by an azepine ring. Azepine is an unsaturated seven-member heterocycle with one nitrogen atom replacing a carbon atom. A dibenzoazepine that is 5H-dibenzoazepine substituted by a 3-(dimethylamino)propyl group at the nitrogen atom. Imipramine is a drug which is used for the relief of symptoms of depression and as temporary adjunctive therapy in reducing enuresis in children aged 6 years and older [fda label].
may also be used off-label to manage panic disorders with or without agoraphobia, as a second line agent for adhd in children and adolescents, to manage bulimia nervosa, for short-term management of acute depressive episodes in bipolar disorder and schizophrenia, for the treatment of acute stress disorder and posttraumatic stress disorder, and for symptomatic treatment of postherpetic neuralgia and painful diabetic neuropathy [l1349,l1348,a31900,l1351,l1352,l1353,a31904]. . Imipramine is a very strong basic compound (based on its pKa). Within humans, imipramine participates in a number of enzymatic reactions. In particular, imipramine can be converted into 2-hydroxyimipramine; which is mediated by the enzyme cytochrome P450 2D6. In addition, imipramine can be converted into desipramine and formaldehyde; which is mediated by the enzymes cytochrome P450 2C19, cytochrome P450 1A2, and cytochrome P450 3A4. In humans, imipramine is involved in imipramine action pathway. Imipramine is a potentially toxic compound. |
---|
Structure | CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12 InChI=1S/C19H24N2/c1-20(2)14-7-15-21-18-10-5-3-8-16(18)12-13-17-9-4-6-11-19(17)21/h3-6,8-11H,7,12-15H2,1-2H3 |
---|
Synonyms | Value | Source |
---|
10,11-Dihydro-N,N-dimethyl-5H-dibenz[b,F]azepine-5-propanamine | ChEBI | 3-(5H-DIBENZO[b,F]azepin-5-yl)-N,N-dimethylpropan-1-amine | ChEBI | 5-[3-(Dimethylamino)propyl]-10,11-dihydro-5H-dibenz[b,F]azepine | ChEBI | Antideprin | ChEBI | Imipramin | ChEBI | Imipraminum | ChEBI | Imizine | ChEBI | Irmin | ChEBI | Melipramine | ChEBI | N-(gamma-Dimethylaminopropyl)iminodibenzyl | ChEBI | Tofranil | Kegg | N-(g-Dimethylaminopropyl)iminodibenzyl | Generator | N-(Γ-dimethylaminopropyl)iminodibenzyl | Generator | Berkomine | HMDB | Chimoreptin | HMDB | Declomipramine | HMDB | Dimipressin | HMDB | DPID | HMDB | Dyna-zina | HMDB | Dynaprin | HMDB | Eupramin | HMDB | Feinalmin | HMDB | Imavate | HMDB | Imidobenzyle | HMDB | Imilanyle | HMDB | Janimine | HMDB | Lofepramine | HMDB | Melipramin | HMDB | Psychoforin | HMDB | Surmontil | HMDB | Surplix | HMDB | Teperine | HMDB | Timolet | HMDB | Tofranil base | HMDB | Tofranil-PM | HMDB | Trimipramine maleate | HMDB | Imipramine hydrochloride | HMDB | Norchlorimipramine | HMDB | Imipramine monohydrochloride | HMDB | Imizin | HMDB | Pryleugan | HMDB | 4,4'-Methylenebis(3-hydroxy-2-naphthoic acid)-3-(10,11-dihydro-5H-dibenzo(b,F)azepin-5-yl)-N,N-dimethyl-1-propanamine (1:2) | HMDB | Imipramine pamoate | HMDB |
|
---|
Chemical Formula | C19H24N2 |
---|
Average Molecular Weight | 280.4073 |
---|
Monoisotopic Molecular Weight | 280.193948778 |
---|
IUPAC Name | (3-{2-azatricyclo[9.4.0.0^{3,8}]pentadeca-1(15),3,5,7,11,13-hexaen-2-yl}propyl)dimethylamine |
---|
Traditional Name | (3-{2-azatricyclo[9.4.0.0^{3,8}]pentadeca-1(15),3,5,7,11,13-hexaen-2-yl}propyl)dimethylamine |
---|
CAS Registry Number | 50-49-7 |
---|
SMILES | CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12 |
---|
InChI Identifier | InChI=1S/C19H24N2/c1-20(2)14-7-15-21-18-10-5-3-8-16(18)12-13-17-9-4-6-11-19(17)21/h3-6,8-11H,7,12-15H2,1-2H3 |
---|
InChI Key | BCGWQEUPMDMJNV-UHFFFAOYSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as dibenzazepines. Dibenzazepines are compounds with two benzene rings connected by an azepine ring. Azepine is an unsaturated seven-member heterocycle with one nitrogen atom replacing a carbon atom. |
---|
Kingdom | Organic compounds |
---|
Super Class | Organoheterocyclic compounds |
---|
Class | Benzazepines |
---|
Sub Class | Dibenzazepines |
---|
Direct Parent | Dibenzazepines |
---|
Alternative Parents | |
---|
Substituents | - Dibenzazepine
- Alkyldiarylamine
- Tertiary aliphatic/aromatic amine
- Azepine
- Benzenoid
- Tertiary aliphatic amine
- Tertiary amine
- Azacycle
- Organic nitrogen compound
- Organopnictogen compound
- Hydrocarbon derivative
- Organonitrogen compound
- Amine
- Aromatic heteropolycyclic compound
|
---|
Molecular Framework | Aromatic heteropolycyclic compounds |
---|
External Descriptors | |
---|
Ontology |
---|
Physiological effect | |
---|
Disposition | |
---|
Process | |
---|
Role | |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | 174.5 °C | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | 18.2 mg/L at 24 °C | Not Available | LogP | 4.80 | HANSCH,C ET AL. (1995) |
|
---|
Experimental Chromatographic Properties | Experimental Collision Cross Sections |
---|
Predicted Molecular Properties | |
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatized |
---|
| GC-MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Experimental GC-MS | GC-MS Spectrum - Imipramine EI-B (Non-derivatized) | splash10-0019-7490000000-3fb4d40b6a219f088ec8 | 2017-09-12 | HMDB team, MONA, MassBank | View Spectrum | Experimental GC-MS | GC-MS Spectrum - Imipramine EI-B (Non-derivatized) | splash10-0019-7490000000-3fb4d40b6a219f088ec8 | 2018-05-18 | HMDB team, MONA, MassBank | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Imipramine GC-MS (Non-derivatized) - 70eV, Positive | splash10-0a4i-7490000000-746fcd08b0a7d6e7bc83 | 2017-08-28 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Imipramine GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Imipramine GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | MS | Mass Spectrum (Electron Ionization) | splash10-0543-8890000000-6cf8e84f007ce7c750f2 | 2014-09-20 | Not Available | View Spectrum |
MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Experimental LC-MS/MS | LC-MS/MS Spectrum - Imipramine Quattro_QQQ 10V, Positive-QTOF (Annotated) | splash10-000i-9000000000-55d924fd00e5b357ce9e | 2012-07-24 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Imipramine Quattro_QQQ 25V, Positive-QTOF (Annotated) | splash10-000i-9000000000-eb3c0ecdffc5d9d95e33 | 2012-07-24 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Imipramine Quattro_QQQ 40V, Positive-QTOF (Annotated) | splash10-0ab9-9432000000-033c51459b692622ee7d | 2012-07-24 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Imipramine EI-B (Unknown) , Positive-QTOF | splash10-0019-7490000000-bb99ef31a755d9f6ba14 | 2012-08-31 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Imipramine LC-ESI-QTOF , positive-QTOF | splash10-052r-9010000000-961429188e57c1480db8 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Imipramine 40V, Positive-QTOF | splash10-0a4i-9000000000-6272981565b197d622f1 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Imipramine -1V, Positive-QTOF | splash10-052r-9010000000-be8c371ae701a7225d13 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Imipramine 40V, Positive-QTOF | splash10-0a4i-9000000000-6c56d64b8822a435898c | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Imipramine 75V, Positive-QTOF | splash10-0a4i-9000000000-2671c52504aa0680b918 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Imipramine 90V, Positive-QTOF | splash10-0a4i-9100000000-a756ccfcc744eec6e5ab | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Imipramine 10V, Positive-QTOF | splash10-0019-9050000000-ad820fcbaa90ad01f5ed | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Imipramine 20V, Positive-QTOF | splash10-000i-9010000000-7b329c019f10b027904f | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Imipramine 45V, Positive-QTOF | splash10-000i-9000000000-18201fd6a82e596bb8bd | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Imipramine 10V, Positive-QTOF | splash10-0019-9050000000-eafe5899fec7b49f5f30 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Imipramine 20V, Positive-QTOF | splash10-000i-9000000000-9adbfb340afaa417fda3 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Imipramine 60V, Positive-QTOF | splash10-0a4r-9000000000-9bb5a8512a91de12e786 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Imipramine 30V, Positive-QTOF | splash10-000i-9000000000-48bfa7137f4eaa6b17e6 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Imipramine 15V, Positive-QTOF | splash10-0019-9080000000-680701a3db1bd34f0e6f | 2021-09-20 | HMDB team, MONA | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Imipramine 10V, Positive-QTOF | splash10-001i-1090000000-d8b2753be1e55651ebe7 | 2017-07-25 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Imipramine 20V, Positive-QTOF | splash10-0019-5190000000-884d5f80618ae379a408 | 2017-07-25 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Imipramine 40V, Positive-QTOF | splash10-000f-9420000000-655018838b0eb1b10c77 | 2017-07-25 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Imipramine 10V, Negative-QTOF | splash10-004i-0090000000-115aa4768e53e232aa16 | 2017-07-26 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Imipramine 20V, Negative-QTOF | splash10-004l-1590000000-bf5870eaefcecc8340c7 | 2017-07-26 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Imipramine 40V, Negative-QTOF | splash10-00kf-2910000000-568ea79e9375b6365408 | 2017-07-26 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Imipramine 10V, Negative-QTOF | splash10-004i-0090000000-fa0545de4a4dc60fd062 | 2021-09-22 | Wishart Lab | View Spectrum |
NMR SpectraSpectrum Type | Description | Deposition Date | Source | View |
---|
Experimental 1D NMR | 1H NMR Spectrum (1D, 500 MHz, CDCl3, experimental) | 2012-12-04 | Wishart Lab | View Spectrum | Experimental 2D NMR | [1H, 13C]-HSQC NMR Spectrum (2D, 600 MHz, CDCl3, experimental) | 2012-12-05 | Wishart Lab | View Spectrum |
|
---|